证券代码：002424 证券简称：贵州百灵 公告编号：2025-044 贵州百灵企业集团制药股份有限公司 关于第六届董事会第二十次会议决议的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚 假记载、误导性陈述或者重大遗漏。 一、会议召开情况 二、会议审议情况 经现场及通讯投票表决，会议审议通过了以下议案： 议案一、审议通过《2025年第三季度报告》。 关于《2025年第三季度报告》详见公司指定信息披露媒体《证券 时报》《证券日报》《中国证券报》《上海证券报》及巨潮资讯网 （http://www.cninfo.com.cn）。 该议案中涉及的财务信息已提前经公司董事会审计委员会审议 通过。 表决结果：同意9票，反对0票，弃权0票,获得通过。 三、备查文件 1、贵州百灵企业集团制药股份有限公司（以下简称"公司"） 第六届董事会第二十次会议由公司董事长姜伟先生召集，会议通知于 2025年10月13日以专人送达、电子邮件、电话等通讯方式发出。 2、本次董事会于2025年10月24日上午10:00在公司三楼会议室以 现场结合通讯方式召开。 3、本次董事会应参会表决董事共9人，实际参会表决的董事9人 ...

贵州百灵企业集团制药股份有限公司 2025 年第三季度报告 证券代码：002424 证券简称：贵州百灵 公告编号：2025-046 贵州百灵企业集团制药股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 贵州百灵企业集团制药股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 639,598,472 ...

贵州百灵公告，第三季度营收为6.4亿元，同比增长1.11%；净利润为497.98万元，同比增长559.90%。 前三季度营收为21.02亿元，同比下降24.28%；净利润为5681.44万元，同比下降35.60%。 ...

Core Insights - The private hospital sector saw a slight increase of 0.29%, ranking 9th among concept sectors, with 32 stocks rising, including Guizhou Bailing and Luoxin Pharmaceutical hitting the daily limit [1][2] Sector Performance - The top-performing concept sectors included Hainan Free Trade Zone (+2.58%) and Military Equipment Restructuring (+1.98%), while sectors like Special Steel (-2.68%) and Photolithography (-2.47%) faced declines [2] - The private hospital sector attracted a net inflow of 201 million yuan, with 29 stocks receiving inflows, and 6 stocks exceeding 50 million yuan in net inflow [2] Stock Highlights - Notable stocks in the private hospital sector included: - New Mileage: +9.87% with a net inflow of 161.24 million yuan and a net inflow ratio of 19.36% [3] - Guizhou Bailing: +9.98% with a net inflow of 95.37 million yuan and a net inflow ratio of 33.91% [3] - Luoxin Pharmaceutical: +9.94% with a net inflow of 77.86 million yuan and a net inflow ratio of 35.07% [3] - Other significant gainers included Hainan Haiyao (+6.14%) and Xinfeng Pharmaceutical (+3.20%) [1][3] Decliners - The stocks with the largest declines included: - Pingtan Development: -4.53% [1] - Xiangjiang Holdings: -3.06% [7] - Anke Biotechnology: -2.48% [7]

证券之星消息，10月16日中药板块较上一交易日上涨0.88%，贵州百灵领涨。当日上证指数报收于 3916.23，上涨0.1%。深证成指报收于13086.41，下跌0.25%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600222 | 太龙药业 | 6.60 | -1.64% | 16.66万 | 1.11亿 | | 002873 | 新天药业 | 10.77 | -1.37% | 7.97万 | 8662.04万 | | 301331 | 恩威医药 | 30.65 | -1.19% | 7822.53 | 2415.53万 | | 300147 | ST香雪 | 10.81 | -1.19% | 14.93万 | 1.64亿 | | 600671 | 天目药业 | 19.43 | -0.97% | 4.99万 | 9770.42万 | | 002198 | 嘉应制药 | 6.51 | -0.91% | 7.83万 | 5121.38万 | | 6660000 | ...

Group 1: Storage Chip Sector Performance - The storage chip sector experienced a significant surge, with companies like Shannon Semiconductor hitting a 20% limit up and reaching new highs [2][4] - Other notable stocks in the sector, such as Cloud Han Chip City and Deming Li, also saw substantial gains, contributing to the overall positive performance of the sector [2][8] - According to TrendForce, the shift of major DRAM manufacturers towards high-end products is expected to drive a 10% to 15% quarterly increase in conventional DRAM prices by Q3 2025, with an overall increase of 15% to 20% when including HBM [4] Group 2: Company-Specific Developments - Shannon Semiconductor's stock rose by 19.04%, closing at 106.78, with a trading volume of 542,100 shares [3] - Other companies in the storage sector, such as Bowe Storage and Jiangbolong, also reported significant price increases, with Bowe Storage rising by 11.11% to 116.00 [3] - Institutional forecasts indicate that 19 stocks in the storage sector are expected to see net profit growth exceeding 50% by 2025 [4] Group 3: Pharmaceutical Sector Activity - The pharmaceutical sector saw renewed activity, with companies like Guizhou Bailing and SanSheng Guojian hitting their respective limit ups [5][6] - Guizhou Bailing's subsidiary received approval for a clinical trial of a new drug aimed at treating type 2 diabetes, marking a significant milestone for the company [10] - The innovative drug sector is projected to maintain high revenue growth, with expectations of continued positive performance in Q3 [10]

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group's subsidiary has received approval for clinical trials of a new traditional Chinese medicine, Tang Ning Tong Luo Pian, aimed at treating Type 2 Diabetes Mellitus (T2DM) and its complications, marking a significant advancement in the company's strategy in the metabolic disease sector [1][2][4] Group 1: Product Development - Tang Ning Tong Luo Pian is the first traditional Chinese medicine to enter clinical trials for both diabetes treatment and its complications in China [1] - The drug has shown promising pharmacological effects by adjusting endocrine functions and improving biochemical indicators in T2DM patients [1][2] - The development of Tang Ning Tong Luo Pian addresses the clinical needs for diabetes prevention, treatment, and management of complications [2][4] Group 2: Market Context - The global diabetes patient population is projected to reach 589 million by 2024, with China having 148 million patients, the highest in the world [2] - The diabetes medication market in China is expected to grow significantly, reaching 116.1 billion yuan by 2025 and 167.5 billion yuan by 2030 [3] - Despite the large market size, a significant portion is dominated by imported drugs, indicating a gap in meeting clinical needs [3] Group 3: Competitive Advantage - Tang Ning Tong Luo Pian is based on Miao medicine principles and has demonstrated unique advantages in treating diabetes and its complications through modern research methods [3][4] - The drug has shown effectiveness in lowering glycosylated hemoglobin levels and delaying the progression of diabetic retinopathy and other complications [3] - If approved, capturing just 1% of the market could yield approximately 2 billion yuan in sales, highlighting its potential impact [4] Group 4: Strategic Vision - The company aims to establish a comprehensive approach to diabetes management through Tang Ning Tong Luo Pian, addressing both prevention and treatment of complications [4] - The chairman of the company emphasized the innovative model of integrating traditional medicine with modern research to enhance the global reach of ethnic medicine [4]

Core Viewpoint - The A-share market continues to show strength in innovative drug concept stocks, with significant gains observed across multiple companies on October 16 [1] Group 1: Stock Performance - Guizhou BaiLing and Luoxin Pharmaceutical reached the daily limit up [1] - Yifang Bio increased by over 7% [1] - Laime Pharmaceutical, Guangsheng Tang, Anglikang, and Shutaishen all rose by over 6% [1] - Dize Pharmaceutical and Lianhuan Pharmaceutical saw increases of over 5% [1]

每经AI快讯，10月16日，中药板块震荡拉升，贵州百灵涨停，维康药业、达仁堂、方盛制药、盘龙药 业、沃华医药跟涨。 （文章来源：每日经济新闻） ...

南方财经10月16日电，中药板块震荡拉升，贵州百灵涨停，维康药业、达仁堂、方盛制药、盘龙药业、 沃华医药跟涨。 ...